Gut microbiota changes after metabolic surgery in adult diabetic patients with mild obesity: a randomised controlled trial

• Type: Article in International Scientific Journal
• Date: 2021

Authors

Eva Lau Gouveia (Author) FMUP; Belda, E (Author) Other; Picq, P (Author) Other; Carvalho, Davide (Author) FMUP; Ferreira Magalhães, M (Author) Other; Silva, MM (Author) Other; Barroso, I (Author) Other; Correia, Flora (Author) FCNAUP; pina-vaz, c (Author) FMUP; Miranda, I (Author) Other; José Barbosa (Author) FMUP; Clément, K (Author) Other; Doré, J (Author) Other; Freitas, P (Author) Other; Prifti, E (Author) Other

Journal

Title: Diabetology and Metabolic Syndrome

Vol. 13

ISSN: 1758-5996

Publisher: Springer Nature

Indexing

ISI Web of Knowledge - 2 Citations

Scopus - 3 Citations

Scientific classification

CORDIS: Health sciences

FOS: Medical and Health sciences

Other information

Authenticus ID: P-00V-0GV

DOI: 10.1186/s13098-021-00672-1

Abstract (EN): Background: Roux-en-Y gastric bypass (RYGB) surgery is one of the most efficient procedures for the treatment of obesity, also improving metabolic and inflammatory status, in patients with mild obesity. The underlying mechanisms have not been fully understood, but gut microbiota is hypothesized to play a key role. Our aim was to evaluate the association between gut microbiota changes and anthropometric, metabolic and inflammatory profiles after metabolic surgery compared with medical therapy, in type 2 diabetic (T2DM) adults with mild obesity (BMI 30¿35 kg/m2). Methods: DM2 was an open-label, randomised controlled clinical trial (RCT: ISRCTN53984585) with 2 arms: (i) surgical, and (ii) medical. The main outcome was gut microbiota changes after: metabolic surgery (Roux-en-Y gastric bypass¿RYGB) versus standard medical therapy. Secondary outcomes included anthropometric, metabolic and inflammatory profiles. Clinical visits, blood workup, and stool samples were collected at baseline and months (M)1, 3, 6, 12. Gut microbiota was profiled using 16S rRNA targeted sequencing. Results: Twenty patients were included: 10 in surgical and 10 in medical arm. Anthropometric and metabolic comparative analysis favoured RYGB over medical arm. At M12, the percentage of weight loss was 25.5 vs. 4.9% (p < 0.001) and HbA1c was 6.2 vs. 7.7% (p < 0.001) respectively. We observed a continuous increase of genus richness after RYGB up until M12. In the medical arm, genus richness ended-up being significantly lower at M12. Composition analysis indicated significant changes of the overall microbial ecosystem (permanova p = 0.004, [R2 = 0.17]) during the follow-up period after RYGB. There was a strong association between improvement of anthropometric/metabolic/inflammatory biomarkers and increase in microbial richness and Proteobacterial lineages. Conclusions: This was the first RCT studying composite clinical, analytic, and microbiome changes in T2DM patients with class 1 obesity after RYGB versus standard medical therapy. The remarkable phenotypic improvement after surgery occurred concomitantly with changes in the gut microbiome, but at a lower level. Trial registration: ISRCTN53984585 © 2021, The Author(s).

Language: English

Type (Professor's evaluation): Scientific